<DOC>
	<DOCNO>NCT00347438</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness capecitabine surgery . The study also help gain information effect capecitabine physical emotional well-being well participant capecitabine follow study drug plan .</brief_summary>
	<brief_title>Capecitabine NeoAdjuvant Therapy Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients locally advance , histologically confirm adenocarcinoma female breast . Women ulcerate breast lesion may enrol . Patients asymptomatic metastasis bone eligible . Ability provide write informed consent prior studyspecific screening procedure TNM Stage : T34 , N03 M0 ; Patients asymptomatic bone metastasis may enrol . Patients large T2 tumor whose surgeon believe result breast conserve surgery improve neoadjuvant therapy may enrol . Age 18 year older Negative serum urine pregnancy test within 7 day prior start therapy ( female patient childbearing potential ) . Performance status 01 Required Initial Laboratory Data : Granulocytes &gt; =1,200/µl Platelet count &gt; =100,000/µl Calculated Creatinine Clearance &gt; 30 mL/min Total bilirubin &lt; = Upper Limit Normal Alkaline Phosphatase &lt; =Upper Limit Normal SGPT , SGOT &lt; =Upper Limit Normal Normal chest xray HER2 positive breast cancer Pregnant lactate woman Life expectancy &lt; 3 month Serious , uncontrolled , concurrent infection ( ) Any prior fluoropyrimidine therapy chemotherapy Prior unanticipated severe reaction fluoropyrimidine therapy , know hypersensitivity 5fluorouracil know DPD deficiency . Patients receive four week tamoxifen therapy malignancy . Treatment carcinoma within last five year , except cure non melanoma skin treat insitu cervical cancer . Participation investigational drug study within 4 week precede start study treatment . Evidence metastatic disease sit bone symptomatic bone lesion . Other serious uncontrolled medical condition investigator feel might compromise study participation . Lack physical integrity upper gastrointestinal tract malabsorption syndrome . Known , exist uncontrolled coagulopathy concurrent treatment Coumadin Phenytoin Any follow laboratory value : Abnormal hematologic value ( neutrophil &lt; 1.0 x 109/L , platelet count &lt; 100 x 109/L ) Impaired renal function ( estimate creatinine clearance &lt; 30ml/min calculated CockcroftGault equation ) Serum bilirubin &gt; upper normal limit . SGOT , SGPT &gt; upper normal limit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>locally advanced</keyword>
</DOC>